Myeloid cell–synthesized coagulation factor X dampens antitumor immunity-Reference-Cited by-同舟云学术

Myeloid cell–synthesized coagulation factor X dampens antitumor immunity

Published:2019-09-13 Issue:39 Volume:4 Page:
ISSN:2470-9468
Container-title:Science Immunology
language:en
Short-container-title:Sci. Immunol.

Author:

Graf Claudine¹²³^ORCID,Wilgenbus Petra¹,Pagel Sven¹,Pott Jennifer¹,Marini Federico¹⁴,Reyda Sabine¹,Kitano Maki²,Macher-Göppinger Stephan⁵,Weiler Hartmut⁶,Ruf Wolfram¹²^ORCID

Affiliation:

1. Center for Thrombosis and Hemostasis, Johannes Gutenberg University Medical Center, Mainz, Germany.

2. Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, USA.

3. Department of Internal Medicine III, Johannes Gutenberg University Medical Center, Mainz, Germany.

4. Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), Johannes Gutenberg University Medical Center, Mainz, Germany.

5. Institute of Pathology, Johannes Gutenberg University Medical Center, Mainz, Germany.

6. Blood Research Institute, Blood Center of Wisconsin, Milwaukee, WI, USA.

Abstract

Rivaroxaban, an inhibitor of coagulation factor Xa, promotes antitumor immunity in mice.

Funder

National Heart, Lung, and Blood Institute

Alexander von Humboldt-Stiftung

Deutsche Forschungsgemeinschaft

Bundesministerium für Bildung und Forschung

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine,Immunology

Reference68 articles.

1. Tissue factor and cell signalling in cancer progression and thrombosis

2. The Platelet Lifeline to Cancer: Challenges and Opportunities

3. Inhibition of tissue factor signaling suppresses tumor growth

4. PAR1 signaling regulates the retention and recruitment of EPCR-expressing bone marrow hematopoietic stem cells

5. Multiple roles of the coagulation protease cascade during virus infection

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anticoagulation for the treatment of immune checkpoint inhibitor–associated venous thromboembolism;Blood Advances;2024-09-24

2. Macrophage fate: to kill or not to kill?;Infection and Immunity;2024-09-10

3. Proteolytic bacteria expansion during colitis amplifies inflammation through cleavage of the external domain of PAR2;Gut Microbes;2024-08-22

4. Activated Factor VII–Antithrombin Complex, a Biomarker of Tissue Factor-Related Pathways in Different Clinical Settings: A Narrative Review from Cardiovascular Diseases to Cancer;Diagnostics;2024-08-06

5. Concomitant Medications Alter Clinical Outcomes in Patients with Advanced Digestive Tract Cancer Receiving PD-1 Checkpoint Inhibitors Combined with Antiangiogenetic Agents;Journal of Gastrointestinal Cancer;2024-07-30